[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 58 of about 58
1. Chen CY, Lin XZ, Wu HC, Shiesh SC: The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies. Clin Biochem; 2005 Jun;38(6):520-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies.
  • BACKGROUND/OBJECTIVES: Elevated concentrations of Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in pancreatic juice have been reported in patients with pancreatic adenocarcinoma and have been considered as a promising tumor marker.
  • This study was conducted to investigate whether biliary HIP/PAP-I can be used in the differential diagnosis of the cause of biliary obstruction.
  • METHODS: Bile was obtained from patients with bile duct obstruction on the day of biliary drainage.
  • The etiology of biliary obstruction included gallstones (n = 131), pancreatic cancer (n = 32), cholangiocarcinoma (n = 47), papilla Vater cancer (n = 13), hepatocellular carcinoma (n = 4) and metastatic cancer (n = 16).
  • RESULTS: The biliary concentration of HIP/PAP-I was not statistically different between patients with gallstones (median, 9.70 ng/mL; interquartile range [IQR] 1.80-45.75) and cancers (median, 12.70 ng/mL; IQR, 3.85-36.75), P > 0.05.
  • At a cut-off value of 46 U/L, the biliary amylase distinguished patients with malignant obstruction from those with benign obstruction with a sensitivity of 66% and a specificity of 74%.
  • CONCLUSIONS: Our data suggest that the biliary HIP/PAP-I measurement is not useful for differentiating causes of biliary obstruction.
  • The divergent extent and duration of biliary obstruction caused by neoplasm and gallstones may contribute to the significant difference in the amylase activity in bile.
  • Thus, amylase in bile represents a candidate marker in the differential diagnosis of the cause of biliary obstruction.
  • [MeSH-major] Amylases / analysis. Antigens, Neoplasm / analysis. Bile / enzymology. Bile Duct Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Lectins, C-Type / analysis
  • [MeSH-minor] Biliary Tract Diseases / diagnosis. Diagnosis, Differential. Female. Humans. Male. Retrospective Studies. Taiwan

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885230.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / pancreatitis-associated protein; EC 3.2.1.- / Amylases
  •  go-up   go-down


2. Iacono C, Bortolasi L, Facci E, Nifosì F, Pachera S, Ruzzenente A, Guglielmi A: The Dagradi-Serio-Iacono operation central pancreatectomy. J Gastrointest Surg; 2007 Mar;11(3):364-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central pancreatectomy (CP) is a segmental pancreatic resection indicated to remove benign or low-grade malignant tumors of the isthmus and proximal part of the body of the pancreas.
  • The main advantage of this operation compared with major resections is that it permits to spare normal pancreatic parenchyma; moreover, spleen and upper digestive and biliary tracts are saved.
  • Subsequently, the pancreatic portion harboring the tumor is isolated at its superior margin from the splenic artery after the pancreas is transacted.
  • Central pancreatectomy is a safe technique for benign or low malignant tumors of the pancreatic neck that allows curing the tumor with evident functional results without increasing the risk for the patient.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):134-40 [15609056.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):266-71 [15864637.001]
  • [Cites] Ann Chir. 2002 Jan;127(1):48-54 [11833306.001]
  • [Cites] Chirurg. 1980 May;51(5):303-7 [7408575.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):730-3 [8751242.001]
  • [Cites] World J Surg. 2003 May;27(5):595-8 [12715230.001]
  • [Cites] J Chir (Paris). 1968 Jan;95(1):5-42 [4878838.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):595-8 [15086212.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):898-903 [2179721.001]
  • [Cites] HPB (Oxford). 2006;8(2):142-7 [18333263.001]
  • [Cites] Am J Surg. 2006 Apr;191(4):549-52 [16531153.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):871-6 [15194067.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Surg Gynecol Obstet. 1959 Oct;109:473-8 [14416087.001]
  • [Cites] Int Surg. 2000 Oct-Dec;85(4):297-302 [11589595.001]
  • [Cites] J Surg Oncol. 2001 Jun;77(2):132-5 [11398167.001]
  • [Cites] Arch Surg. 2006 Apr;141(4):361-5; discussion 366 [16618893.001]
  • [Cites] Surg Today. 1993;23(8):733-6 [8400678.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Chirurg. 2003 Oct;74(10 ):961-5 [14605740.001]
  • [Cites] Chirurg. 2004 Jun;75(6):615-21 [15103421.001]
  • [Cites] Br J Surg. 2005 May;92(5):539-46 [15852419.001]
  • [Cites] Dig Surg. 2004;21(1):48-53 [14707393.001]
  • [Cites] Mem Acad Chir (Paris). 1957 Nov 13-20;83(27-28):869-71 [13503655.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):293-9 [16549696.001]
  • [Cites] Chirurgie. 1998 Sep;123(4):363-7 [9828510.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2585-8 [10522046.001]
  • [Cites] Dig Surg. 2003;20(6):506-10 [14506331.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1023-8 [9261593.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):719 [3416130.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):233-6 [15783038.001]
  • (PMID = 17458612.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Tantau M, Pop T, Badea R, Spirchez Z, Moşteanu O, Tantau A: Intraductal ultrasonography for the assessment of preoperative biliary and pancreatic strictures. J Gastrointestin Liver Dis; 2008 Jun;17(2):217-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal ultrasonography for the assessment of preoperative biliary and pancreatic strictures.
  • Diseases of the biliary and pancreatic ducts are often difficult to diagnose.
  • Although transcutaneous ultrasonography, computer tomography and magnetic resonance greatly improved in performance, two major problems have not been completely solved yet: first, the differentiation of malignant and benign bile duct strictures, and, second, the assessment of the resectability of carcinomas underlying biliary strictures.
  • Ultrasound probes can be inserted through the working channel of the duodenoscope and passed selectively both into the biliary and pancreatic ducts.
  • The main clinical indication for intraductal ultrasonography of the biliary tract is obstructive jaundice, which requires assessment of bile duct strictures and local tumor staging.

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568147.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 25
  •  go-up   go-down


Advertisement
4. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg; 2009 Sep;198(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
  • BACKGROUND: Obstructive jaundice is frequently associated with false CA19-9 elevation in benign conditions.
  • The diagnostic accuracy of this tumor marker was evaluated in the present longitudinal study.
  • METHODS: In 128 patients admitted for obstructive jaundice (87 with pancreato-biliary malignancy and 41 benign disease) serum CA19-9 was measured.
  • Statistical analysis of marker levels obtained before and after endoscopic biliary drainage was performed in 60 patients.
  • RESULTS: Elevated CA19-9 levels (>37 U/mL) were found in 61% of benign cases and 86% of malignancies.
  • After biliary drainage, decrease of serum CA19-9 was observed in 19 of 38 malignant cases and in almost all benign cases (Wilcoxon matched pairs test: P = .207 and P <.001, respectively).
  • Receiver operating characteristic (ROC) analysis identified a cut-off value of 90 U/mL to be associated with improved diagnostic accuracy after biliary drainage (sensitivity 61%, specificity 95%).
  • [MeSH-major] Biliary Tract Neoplasms / blood. CA-19-9 Antigen / blood. Jaundice, Obstructive / blood. Pancreatic Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Drainage. Female. Humans. Male. Middle Aged. Predictive Value of Tests. ROC Curve. Sensitivity and Specificity. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375064.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


5. Kim YS, Gupta K, Mallery S, Li R, Kinney T, Freeman ML: Endoscopic ultrasound rendezvous for bile duct access using a transduodenal approach: cumulative experience at a single center. A case series. Endoscopy; 2010 Jun;42(6):496-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasound (EUS)-assisted biliary access is utilized when conventional endoscopic retrograde cholangiopancreatography (ERCP) fails.
  • We report a 10-year experience utilizing a transduodenal EUS rendezvous via a transpapillary route without dilation of the transduodenal tract, followed by immediate ERCP access.
  • Patients included all EUS-guided rendezvous procedures for biliary access that were performed following ERCP failure.
  • EUS-assisted bile duct puncture was performed via a transduodenal approach and a guide wire was advanced through the papilla without any dilation or bougienage of the tract; ERCP was performed immediately afterwards.
  • EUS-assisted biliary rendezvous was attempted in 15 patients (mean age 66 +/- 18.2 years; malignant = 10, benign = 5).
  • The reasons for initial ERCP failure were tumor infiltration or edema (n = 9), intradiverticular papilla (n = 2), pre-existing duodenal stent (n = 1), and anatomic anomalies (n = 3).
  • Failures occurred in three patients due to inability to traverse the biliary stricture (n = 2) or dissection of a choledochocele with the guide wire (n = 1); all were subsequently drained via percutaneous methods.
  • Complications consisted of moderate pancreatitis after a difficult ERCP attempt in one patient, and bacteremia after percutaneous biliary drainage in another.
  • EUS-assisted biliary drainage utilizing a transduodenal rendezvous approach demonstated a high success rate without any complications directly attributable to the EUS access.
  • Advantages over percutaneous biliary and other methods of EUS biliary access include performance under the same anesthesia, and a very small-caliber needle puncture similar to EUS/fine-needle aspiration.

  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20419625.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult.
  • Tissue-microarrays including 20 esophageal, 86 gastric, 8 small bowel, 64 colonic, 18 pancreatic, 6 gallbladder, and 7 extrahepatic biliary tract adenocarcinomas, 22 hepatocellular carcinomas, and normal tissues were constructed.
  • All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin.
  • The expression of N-cadherin at the plasma membrane of tumor cells was significantly more frequent in peripheral than in hilar intrahepatic cholangiocarcinomas (P=0.003).
  • Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells.
  • In the gastrointestinal and liver tract, membranous N-cadherin is restricted to the hepatocytes and intrahepatic biliary cells.
  • [MeSH-major] Antigens, CD / analysis. Bile Duct Neoplasms / immunology. Bile Ducts, Intrahepatic / immunology. Biomarkers, Tumor / analysis. Cadherins / analysis. Cholangiocarcinoma / immunology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


7. Mann CM, Bramhall SR, Buckels JA, Taniere P: An unusual case of duodenal obstruction-gangliocytic paraganglioma. J Hepatobiliary Pancreat Surg; 2009;16(4):562-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliocytic paragangliomas are rare tumors located in the gastrointestinal tract that are considered to be benign.
  • Intraoperatively, the patient was found to have local tumor extension and regional lymph node invasion, and so she underwent a pylorus-preserving pancreaticoduodenectomy, with local lymph node clearance.
  • [MeSH-minor] Adolescent. Endoscopy, Digestive System. Female. Humans. Lymph Nodes / pathology. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517054.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Thomas KT, Welch D, Trueblood A, Sulur P, Wise P, Gorden DL, Chari RS, Wright JK Jr, Washington K, Pinson CW: Effective treatment of biliary cystadenoma. Ann Surg; 2005 May;241(5):769-73; discussion 773-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of biliary cystadenoma.
  • SUMMARY BACKGROUND DATA: Biliary cystadenoma, a benign hepatic tumor arising from Von Meyenberg complexes, usually present as septated intrahepatic cystic lesions.
  • Pathology specimens were rereviewed to confirm the diagnosis of biliary cystadenoma or biliary cystadenocarcinoma by 2 GI pathologists.
  • RESULTS: From October 1989 to April 2004 at our institution, 19 (18F:1M) patients had pathologically confirmed biliary cystadenomas, including one with a biliary cystadenocarcinoma.
  • CONCLUSIONS: Biliary cystadenoma must be recognized and treated differently than most hepatic cysts.
  • There remains a need for education about the imaging findings for biliary cystadenoma to reduce the demonstrated delay in appropriate treatment.
  • [MeSH-major] Biliary Tract Neoplasms / surgery. Cystadenoma / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Jan-Feb;48(37):250-2 [11268977.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1621-4 [14571799.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):895-910 [11452064.001]
  • [Cites] Clin Radiol. 2003 Aug;58(8):626-9 [12887956.001]
  • [Cites] Arch Surg. 1971 Jan;102(1):78-80 [5538773.001]
  • [Cites] Arch Surg. 1974 Jul;109(1):41-3 [4834134.001]
  • [Cites] Cancer. 1977 Jan;39(1):322-38 [318915.001]
  • [Cites] Surg Clin North Am. 1977 Apr;57(2):449-64 [322342.001]
  • [Cites] Clin Oncol. 1982 Jun;8(2):171-7 [7105527.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1434-45 [4027877.001]
  • [Cites] Am J Gastroenterol. 1986 Feb;81(2):138-40 [3946368.001]
  • [Cites] Obstet Gynecol. 1987 Sep;70(3 Pt 2):466-8 [3627604.001]
  • [Cites] Arch Surg. 1988 May;123(5):563-8 [3358682.001]
  • [Cites] Surg Gynecol Obstet. 1989 Jun;168(6):534-7 [2727881.001]
  • [Cites] Gastrointest Radiol. 1990 Fall;15(4):313-6 [2210204.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1841-6 [1525758.001]
  • [Cites] Arch Pathol Lab Med. 1993 Oct;117(10):1036-42 [8215827.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):619-25 [7487208.001]
  • [Cites] J Gastroenterol. 1996 Oct;31(5):732-6 [8887044.001]
  • [Cites] Magn Reson Imaging Clin N Am. 1997 May;5(2):289-318 [9113676.001]
  • [Cites] J Surg Oncol. 1997 Apr;64(4):341-6 [9142194.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):348-52 [9880787.001]
  • [Cites] J Am Coll Surg. 2001 Jul;193(1):36-45 [11442252.001]
  • (PMID = 15849512.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1357131
  •  go-up   go-down


9. Linder S, Söderlund C: Factors influencing the use of precut technique at endoscopic sphincterotomy. Hepatogastroenterology; 2007 Dec;54(80):2192-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Endoscopic sphincterotomy (EST) is a prerequisite for invasive procedures in the biliary tract or the pancreas.
  • Precutting was used less frequently in patients with biliary stone disease, in 39 of 183, than in those without (P < 0.01).
  • In the presence of a tumor, precut technique was warranted more often, in 62 of 143, as compared to benign disease, 111 of 419 (P < 0.01).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biliary Tract Neoplasms / surgery. Catheterization. Female. Gallstones / surgery. Humans. Male. Middle Aged. Multivariate Analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265631.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Lapkus O, Gologan O, Liu Y, Swalsky PA, Wilson MM, Finkelstein SD, Silverman JF: Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol; 2006 Jul;19(7):907-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplastic progression is characterized by clonal expansion of tumor cells associated with accumulation of mutational damage.
  • The timing of mutation acquisition could be of value in distinguishing preneoplastic conditions from early and advanced cancer as well as characterizing tumor aggressiveness and treatment response.
  • In all, 40 pancreatic duct and 21 biliary brushing cytology specimens were retrieved from the cytology database.
  • Clusters of benign, atypical and malignant cells were manually microdissected and DNA extracted.
  • While there was overlap in the spectrum of mutational markers in pancreatic duct and biliary brushing cytology, the temporal profile was significantly different (P<0.001).
  • Pancreatic and biliary neoplasia progression involves distinct subset of accumulated defined mutations.
  • [MeSH-major] Biliary Tract Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Mutation. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648872.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


11. Wojtuń S, Gil J, Zyśko B: [The use of endoscopic method in treatment of strictures of biliary tree]. Pol Merkur Lekarski; 2007 May;22(131):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of endoscopic method in treatment of strictures of biliary tree].
  • The strictures of bilitary tree may occur as a result of benign and malignant pathologies of liver and pancreas.
  • The benign stricture of biliary tree are usually results of the surgery and if it is possible the endoscopic methods should be implemented in this group of patients.
  • In case of the stricture of biliary tree in the course of the chronic pancreatitis a surgery should be chosen, because the widening and endoscopic stenting don't allow the long term removal of stricture.
  • The treatment of malignant stricture of biliary tree depends on the early diagnosis, placement and the extension of malignant lesion.
  • Palliative surgical treatment is usually used in laparotomy, when the non-removable tumor was diagnosed.
  • In case of disqualification of the patient from surgical treatment in palliative treatment of malignant stricture of biliary tree, the method of choice is the endoscopic treatment and in case of failure from the pericotaneous drainage should be applied.
  • The study shows some of the treatment methods and the combination of different techniques, which may be used in case of bile flow obstruction because of the stricture of biliary tree.
  • [MeSH-major] Biliary Tract Surgical Procedures. Catheterization. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis, Extrahepatic / therapy. Cholestasis, Intrahepatic / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679400.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 24
  •  go-up   go-down


12. Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Moriyasu F, Gotoda T: Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc; 2007 Oct;66(4):730-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos).
  • BACKGROUND: Narrow-band imaging (NBI) makes it possible to emphasize the imaging of certain features, such as mucosal structures and mucosal microvessels in GI-tract diseases.
  • OBJECTIVE: To evaluate the clinical usefulness of POCS by using NBI for the diagnosis of biliary-tract diseases.
  • PATIENTS: Twelve consecutive patients with biliary-tract diseases, including 7 bile-duct cancers and 5 benign biliary diseases, which revealed 6 bile-duct strictures and 6 filling defects by ERCP.
  • CONCLUSIONS: POCS by using NBI may be helpful for the observation of both fine mucosal structures and tumor vessels.
  • [MeSH-major] Biliary Tract Diseases / diagnosis. Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Video Recording / methods

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2007 Oct;66(4):737-9 [17905016.001]
  • (PMID = 17905015.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Yu FC, Chen JH, Yang KC, Wu CC, Chou YY: Hepatobiliary cystadenoma: a report of two cases. J Gastrointestin Liver Dis; 2008 Jun;17(2):203-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal echo revealed biliary tracts dilatation; ERCP revealed amorphous filling defect inside the dilated CBD, a cystic tumor in the left lobe communicated with bile duct was disclosed by MRI/MRCP.
  • Abdominal ultrasound detected a huge cystic tumor over the left hepatic lobe in a 69-year-old male.
  • A liver biopsy was performed and microscopic findings proved biliary cystadenoma.
  • Hepatobiliary cystadenoma is a rare benign cystic tumor of the liver.
  • Elevated serum and cystic fluid tumor markers CA19-9 are only seen in some patients; cystic fluid cytology does not provide adequate diagnostic aid.
  • Its morphologic features maybe confused with biliary papillomatosis or IPMN of bile duct.
  • [MeSH-major] Bile Ducts, Intrahepatic. Biliary Tract Neoplasms / diagnosis. Cystadenoma / diagnosis. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568143.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


14. Modlin IM, Shapiro MD, Kidd M: An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg; 2005 Jan;29(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though commonly associated with the gastrointestinal tract and bronchopulmonary system, a substantial number of these tumors originate in less common anatomical sites and can range from indolent, unrecognized entities to highly active, metastatic secretory tumors.
  • The primary organs in which carcinoids are most commonly mistaken for some of the more conspicuous endemic tumors include the esophagus, pancreas, liver, biliary tract, gallbladder, and Meckel's diverticulum, as well as within the pelvic and otolaryngeal organs and the breast.
  • In general, the highest proportion of "rare" carcinoids was identified in the gastrointestinal (GI) tract, with the ovary as the single most affected extra-GI site.
  • The diminution of the likelihood of inadvertently neglecting these often benign, indolent neoplasms that are well known to metastasize if unaddressed would represent an important advance.
  • [MeSH-major] Carcinoid Tumor / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):153-8 [8604242.001]
  • [Cites] Ultrastruct Pathol. 1993 Jan-Feb;17(1):115-21 [8427027.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):229-35 [7546678.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1705-13 [6383596.001]
  • [Cites] Patol Pol. 1978 Apr-Jun;29(2):237-40 [704186.001]
  • [Cites] N Y State J Med. 1969 May 15;69(10):1337-9 [5255420.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1334-9 [11688471.001]
  • [Cites] Lancet. 1954 Nov 6;267(6845):951 [13213086.001]
  • [Cites] Z Gastroenterol. 1974 Sep;12 Suppl(0):377-84 [4418379.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):897-909 [1707237.001]
  • [Cites] Intern Med. 1996 Dec;35(12 ):953-6 [9030993.001]
  • [Cites] J Urol. 1977 Nov;118(5):777-82 [916100.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2189-95 [10521965.001]
  • [Cites] J Gastroenterol. 1995 Jun;30(3):398-402 [7647908.001]
  • [Cites] Cancer. 1975 Aug;36(2):404-18 [1157010.001]
  • [Cites] Digestion. 1997;58(4):410-4 [9324172.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):187-211 [8173736.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Ital J Surg Sci. 1986;16(4):249-53 [3557930.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):259-65 [8626144.001]
  • [Cites] Thorax. 1989 Jul;44(7):594-6 [2672408.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1726-32 [7688660.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):93-5 [7679854.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1109-16 [8758239.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4209-13 [10566674.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):281-3 [7789401.001]
  • [Cites] Pathol Annu. 1979;14 Pt 1:273-91 [42037.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):217-20 [2776604.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):281-8 [7673859.001]
  • [Cites] Z Gastroenterol. 1998 Mar;36(3):233-8 [9577907.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):141-8 [10713946.001]
  • [Cites] J Urol. 1954 Nov;72(5):892-4 [13212896.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Int J Urol. 2001 Sep;8(9):522-4 [11683977.001]
  • [Cites] Histopathology. 1987 Jan;11(1):53-62 [2881873.001]
  • [Cites] J Am Osteopath Assoc. 2000 Jul;100(7):432-4 [10943090.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1462-7 [9840084.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):547-52 [2164339.001]
  • [Cites] J Laryngol Otol. 1983 Nov;97(11):1073-80 [6644166.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Acta Oncol. 1993;32(2):225-9 [7686765.001]
  • [Cites] Heart. 1998 Dec;80(6):623-6 [10065036.001]
  • [Cites] Jpn J Clin Oncol. 1989 Dec;19(4):397-401 [2607641.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1959-65 [10570419.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1501-10 [11075851.001]
  • [Cites] Ear Nose Throat J. 2002 Jan;81(1):40-3 [11816388.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Ann R Coll Surg Engl. 1959 Dec;25(5):277-97 [19310224.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] Arch Otolaryngol. 1969 Jul;90(1):64-7 [5785991.001]
  • [Cites] Can J Surg. 1999 Feb;42(1):59-63 [10071590.001]
  • [Cites] Acta Cytol. 1990 Mar-Apr;34(2):119-24 [2181800.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):261-4 [9607629.001]
  • [Cites] Diagn Cytopathol. 2001 Sep;25(3):168-71 [11536440.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:159-69 [12381551.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):589-96 [1587179.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):609-12 [8631405.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):23-32 [14687136.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Arch Anat Pathol (Paris). 1964 Sep;12:200-3 [14228034.001]
  • [Cites] Am J Clin Pathol. 1980 Jun;73(6):816-23 [6156597.001]
  • (PMID = 15599742.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


15. Halazun KJ, Al-Mukhtar A, Aldouri A, Malik HZ, Attia MS, Prasad KR, Toogood GJ, Lodge JP: Right hepatic trisectionectomy for hepatobiliary diseases: results and an appraisal of its current role. Ann Surg; 2007 Dec;246(6):1065-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 275 patients, 160 had colorectal metastases, 49 had biliary tract cancers, 20 had hepatocellular carcinomas, 20 had other metastatic tumors, and 12 had benign diseases.
  • Concomitant procedures were carried out in 192 patients: caudate lobectomy in 45 patients, resection of tumors from the liver remnant in 57 patients, resection of the extrahepatic biliary tree in 45 patients, and lymphadenectomy in 45 patients.
  • Survivals for individual tumor types were acceptable, with 5-year survivals for colorectal metastasis and cholangiocarcinoma being 38% and 32%, respectively.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Jul;248(1):138-9; author reply 139-40 [18580219.001]
  • (PMID = 18043112.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, Corradini SG, Invernizzi P, Franchitto A, Attili AF, Gaudio E, Benedetti A: Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med; 2007 Oct 2;147(7):451-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
  • PATIENTS: 73 patients who consecutively had endoscopic retrograde cholangiopancreatography (ERCP), including patients with extrahepatic cholangiocarcinoma (n = 29), pancreatic cancer (n = 19), and benign biliary abnormalities (n = 25; bile duct stones, primary sclerosing cholangitis, and cholangitis).
  • RESULTS: The biliary IGF-I concentration was 15- to 20-fold higher (P < 0.001) in extrahepatic cholangiocarcinoma (mean, 84.6 nmol/L [95% CI, 74.0 to 95.2 nmol/L]) than in pancreatic cancer (5.8 nmol/L [CI, 4.0 to 7.5 nmol/L]) or benign biliary abnormalities (4.1 nmol/L [CI, 3.1 to 5.2 nmol/L]).
  • The area under the receiver-operating characteristic curve was 1 when biliary IGF-I values in the extrahepatic cholangiocarcinoma were compared with benign biliary abnormalities or pancreatic cancer.
  • In contrast, biliary VEGF concentration was similar in the 3 groups.
  • Serum IGF-I levels were similar among the groups, whereas serum VEGF levels were higher in the cholangiocarcinoma (0.97 ng/mL [CI, 0.59 to 1.35 ng/mL]; P = 0.0016) and pancreatic cancer groups (0.66 ng/mL [CI, 0.43 to 0.88 ng/mL]; P < 0.001) compared with patients with benign biliary abnormalities (0.28 ng/mL [CI, 0.17 to 0.37 ng/mL]).
  • CONCLUSIONS: Biliary IGF-I levels in patients undergoing ERCP for biliary obstruction may differentiate extrahepatic cholangiocarcinoma from either pancreatic cancer or benign biliary abnormalities.
  • [MeSH-major] Bile / chemistry. Bile Duct Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Cholangiocarcinoma / diagnosis. Cholestasis / etiology. Insulin-Like Growth Factor I / analysis. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Biliary Tract Diseases / complications. Biliary Tract Diseases / diagnosis. Cross-Sectional Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / diagnosis. ROC Curve

  • Genetic Alliance. consumer health - Cholestasis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Intern Med. 2007 Nov 6;147(9):676
  • (PMID = 17909206.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


17. Yamaguchi K, Nakano K, Nagai E, Chijiiwa K, Kinoshita M, Ohta M, Tanaka M: Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. Hepatogastroenterology; 2005 May-Jun;52(63):713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: The differentiation between benign and malignant jaundice is sometimes difficult even with modern diagnostic modalities.
  • METHODOLOGY: Cytologic examination and novel biomarkers, point mutations of codon 12 of Ki-ras and p53 mutations, were examined in the biliary tract bile aspirated through percutaneous transhepatic biliary drainage (PTBD) tube in 30 Japanese patients with benign and malignant hepatobiliary and pancreatic diseases.
  • [MeSH-major] Bile / cytology. Bile Duct Neoplasms / genetics. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Biomarkers, Tumor / genetics. Codon / genetics. DNA Mutational Analysis. Genes, ras / genetics. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966189.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Codon; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


18. Ventrucci M, Pozzato P, Cipolla A, Uomo G: Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis; 2009 May;41(5):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Serum CA 19-9 is the mainstay marker for the diagnosis of biliopancreatic malignancies, though a persistent elevation can also be observed in various benign diseases.
  • METHODS: Routine blood tests, tumour marker determinations, imaging studies and endoscopy were carried out at admission.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Liver Dis. 2010 Jun;42(6):458-9 [19880358.001]
  • (PMID = 18602352.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


19. Gamblin TC, Krasinskas AM, Slivka AS, Tublin ME, Demetris J, Shue E, Caro S, Marsh JW, James Moser A: Fibroinflammatory biliary stricture: a rare bile duct lesion masquerading as cholangiocarcinoma. J Gastrointest Surg; 2009 Apr;13(4):713-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroinflammatory biliary stricture: a rare bile duct lesion masquerading as cholangiocarcinoma.
  • INTRODUCTION: Fibroinflammatory biliary stricture (FIBS) is a rare benign tumor-like process of the extrahepatic bile duct that masquerades as cholangiocarcinoma.
  • Preoperative evaluation included computed tomography scan and endoscopic retrograde cholangiopancreatography with benign brush cytology.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Nucl Med Commun. 2007 Dec;28(12 ):914-9 [18090217.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 30;317(2):451-62 [15063779.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1193-203 [15316319.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):494-9 [8299916.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1538-46 [17518371.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):219-24 [9334845.001]
  • [Cites] Hepatology. 1989 Oct;10(4):430-6 [2777204.001]
  • [Cites] Intern Med. 2006;45(8):497-501 [16702740.001]
  • [Cites] J Radiol. 2006 Dec;87(12 Pt 1):1894-6 [17213776.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):152-7 [15990840.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):659-61 [4027545.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):747-53 [8651355.001]
  • [Cites] Ital J Gastroenterol. 1996 Apr;28(3):152-9 [8789826.001]
  • [Cites] Surgery. 1992 Nov;112(5):866-71 [1332203.001]
  • [Cites] J Thorac Surg. 1954 Jul;28(1):55-63 [13175281.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):567-78 [6625050.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1230-3 [11100320.001]
  • [Cites] Br J Surg. 1983 Mar;70(3):166-71 [6831158.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(4):314-6 [16133699.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1626-34 [2311072.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):849-52 [2765843.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):588-90 [11923781.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):313-24 [8772785.001]
  • [Cites] Histopathology. 1984 Nov;8(6):903-16 [6098549.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):23-8 [16980948.001]
  • [Cites] Pathol Res Pract. 1997;193(7):519-25; discussion 526 [9342759.001]
  • [Cites] J Pediatr. 1978 Oct;93(4):628-30 [702242.001]
  • [Cites] Surgery. 2006 Nov;140(5):756-63 [17084718.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):427-32 [14760772.001]
  • [Cites] J Am Coll Surg. 2005 Dec;201(6):862-9 [16310689.001]
  • [Cites] J Magn Reson Imaging. 2007 Aug;26(2):304-12 [17623893.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1993 Sep;94(9):1064-7 [8246873.001]
  • [Cites] J Clin Gastroenterol. 1988 Oct;10(5):579-83 [3183330.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1433-7 [8111710.001]
  • [Cites] Pancreas. 2005 Jan;30(1):31-9 [15632697.001]
  • [Cites] Pancreatology. 2006;6(1-2):132-7 [16327291.001]
  • [Cites] Gastrointest Endosc. 2007 May;65(6):832-41 [17466202.001]
  • [Cites] Gut. 2004 Dec;53(12):1860-5 [15542529.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):57-62; discussion 62-3 [1846276.001]
  • [Cites] J Clin Gastroenterol. 1995 Sep;21(2):143-8 [8583081.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 6;99(11):895-7 [17551150.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1146-56 [1746682.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1093-8 [7557942.001]
  • (PMID = 19057967.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-51485; United States / NICHD NIH HHS / HD / K12 HD 049109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


20. Leelawat K, Narong S, Wannaprasert J, Ratanashu-ek T: Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol; 2010 Oct 7;16(37):4697-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine whether the serum level of matrix metalloproteinase-7 (MMP7) has the potential to diagnosis cholangiocarcinoma from benign biliary tract diseases.
  • This was conducted in a blinded case (cholangiocarcinoma)-control (benign biliary tract disease) setup.
  • CONCLUSION: Serum values of MMP7 and CA19-9 appear to be useful biomarkers for differentiating cholangiocarcinoma from benign biliary tract obstructive diseases.
  • [MeSH-major] Biomarkers, Tumor / blood. Cholangiocarcinoma. Matrix Metalloproteinase 7 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2003 Jan 4;361(9351):71 [12517476.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):428-34 [11900228.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1259-62 [14571713.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2832-45 [15102692.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Gut. 1999 Aug;45(2):252-8 [10403738.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3313-6 [10416584.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):355-60 [16191503.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4195-8 [16830373.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1066-71 [17487834.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1174-84 [17919228.001]
  • [Cites] Clin Liver Dis. 2008 Feb;12(1):131-50, ix [18242501.001]
  • [Cites] Curr Opin Gastroenterol. 2008 May;24(3):349-56 [18408464.001]
  • [Cites] Hum Pathol. 2008 May;39(5):710-9 [18329694.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] PLoS One. 2008;3(7):e2633 [18612378.001]
  • [Cites] BMC Med Res Methodol. 2008;8:48 [18644127.001]
  • [Cites] Radiology. 2008 Sep;248(3):713-4 [18710968.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8 [18840817.001]
  • [Cites] Dig Dis Sci. 2008 Dec;53(12):3213-7 [18465243.001]
  • [Cites] BMC Gastroenterol. 2009;9:30 [19405942.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1649-57 [19690958.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):19-20 [12507955.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] J Pathol. 2003 Feb;199(2):176-84 [12533830.001]
  • (PMID = 20872971.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ PMC2951521
  •  go-up   go-down


21. Kim BJ, Lee KT, Moon TG, Kang P, Lee JK, Kim JJ, Rhee JC: How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Dig Liver Dis; 2009 May;41(5):364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 97 patients (27.5%) with benign diseases and 246 patients (69.7%) were deemed non-specific.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Liver Dis. 2010 Mar;42(3):234-5 [19574113.001]
  • [CommentIn] Dig Liver Dis. 2009 May;41(5):325-7 [19297258.001]
  • [CommentIn] Dig Liver Dis. 2010 Jan;42(1):73-4 [19473891.001]
  • (PMID = 19162573.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


22. Hori T, Wagata T, Takemoto K, Shigeta T, Takuwa H, Hata K, Uemoto S, Yokoo N: Spontaneous necrosis of solid gallbladder adenocarcinoma accompanied with pancreaticobiliary maljunction. World J Gastroenterol; 2008 Oct 14;14(38):5933-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We were agonized in making the qualitative diagnosis of mass-like lesions of the fundus, such as a benign tumor, cancer, or debris.
  • [MeSH-major] Adenocarcinoma / pathology. Biliary Tract / abnormalities. Gallbladder Neoplasms / pathology. Incidental Findings. Pancreas / abnormalities
  • [MeSH-minor] Aged. Cholangiography. Cholecystectomy, Laparoscopic. Cholecystitis, Acute / surgery. Fatal Outcome. Gallstones / surgery. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Necrosis. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gallbladder adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):208-12 [16377119.001]
  • [Cites] Vnitr Lek. 2004 Oct;50(10):781-5 [15633935.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):355-61 [17693282.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1188-93 [17712596.001]
  • [Cites] Postgrad Med J. 2000 Feb;76(892):96-8 [10644387.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):631-5 [10919001.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(1):95-100 [11294297.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):340-8 [11466688.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):447-54 [12734095.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2086-8 [6627217.001]
  • [Cites] Surg Gastroenterol. 1984;3(2):69-73 [6085899.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Eur J Endocrinol. 1994 May;130(5):469-71 [8180674.001]
  • [Cites] Hepatogastroenterology. 1995 Apr;42(2):113-6 [7545638.001]
  • [Cites] Br J Urol. 1995 Oct;76(4):501-3 [7551893.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1224-5 [9373301.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):62-8 [9426519.001]
  • [Cites] Cancer Invest. 1998;16(1):64-5 [9474255.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):423-7 [9690533.001]
  • [Cites] Am Surg. 1998 Aug;64(8):764-7 [9697909.001]
  • [Cites] J Clin Endocrinol Metab. 1953 Aug;13(8):997-1008 [13069604.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2549-55 [16688800.001]
  • (PMID = 18855999.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2751910
  •  go-up   go-down


23. Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A: Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol; 2007 Oct 28;13(40):5357-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: CA 19-9 is a tumor-associated antigen, which is elevated in pancreatic, upper gastrointestinal tract, ovarian hepatocellular, and colorectal cancers, as well as in inflammatory conditions of the hepatobiliary system, biliary obstruction and in thyroid diseases.
  • We propose that a higher cut-off value of CA 19-9 should be used in diabetics to differentiate benign and malignant pancreatic disease, and subtle elevations of CA 19-9 in diabetics should be considered as the indication of exocrine pancreatic dysfunction.


24. Deng FT, Li YX, Ye L, Tong L, Yang XP, Chai XQ: Hilar inflammatory pseudotumor mimicking hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2010 Apr;9(2):219-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Inflammatory pseudotumor of the biliary tract is a benign disease, and is extremely rare.
  • The evaluation involves clinical manifestations, imaging appearance and tumor markers.
  • Malignant tumors and possible benign lesions should be considered to avoid aggressive surgical treatment.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382598.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


25. Koroglu M, Koroglu BK, Akhan O, Coskun HS, Yildizz H, Yesildag A, Oyar O: Effect of percutaneous biliary drainage on serum levels of tumor markers in patients with obstructive jaundice. Hepatogastroenterology; 2006 Jul-Aug;53(70):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of percutaneous biliary drainage on serum levels of tumor markers in patients with obstructive jaundice.
  • BACKGROUND/AIMS: Some tumor markers such as CA 19-9 are shown to be increased in obstructive jaundice due to either benign or malignant causes.
  • In this study the clinical importance of raised serum levels of tumor markers have been evaluated, with particular reference to obstructive jaundice and percutaneous biliary drainage.
  • Twenty-one patients with obstructive jaundice were investigated, 5 with benign obstruction and 16 with malignant disease.
  • All patients were examined with abdominal CT prior to biliary drainage.
  • All patients underwent percutaneous transhepatic cholangiography, and 20 of 21 patients underwent percutaneous biliary drainage within 3 days after the CT examination.
  • RESULTS: The mean CA 19-9 at presentation was lower in the group with benign disease (95 +/- 60.9 IU/mL) than those with malignancy (461.9 +/- 331.4 IU/mL).
  • The mean CA 19-9 level in the benign group 1 week after drainage was 12 +/- 11.8 IU/mL.
  • CONCLUSIONS: A prominently high serum CA 19-9 level at the presentation and a high serum CA 19-9 level after successful biliary drainage should prompt investigation for a malignant etiology of obstructive jaundice.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Drainage / methods. Jaundice, Obstructive / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract Diseases / radiography. Cholangiography. Digestive System Neoplasms / radiography. Female. Humans. Liver / enzymology. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995447.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


26. Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep; 2009 Nov;22(5):1149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of CD24 expression by immunohistochemistry was 68% in all the carcinomas of the breast, female genital tract, gastrointestinal tract, biliary tract and pancreas, urinary system, prostate and skin.
  • Overall, CD24 was more frequently overexpressed in their carcinomas than their benign lesions (OR=4.21; 95% CI, 1.826-9.731; P=0.001) and was significantly associated with lymph node metastasis (OR=2.41; CI, 1.013-5.720; P=0.047), advanced clinical stages (OR=1.59; 95% CI, 1.244-2.032; P<0.001) and shortened overall survival (HR=2.13; 95% CI, 1.656-2.730; P<0.001).
  • CD24 was more frequently and strongly expressed in breast (OR=35.80; 95% CI, 8.907-143.921; P<0.001) and ovarian carcinomas (OR=35.92; CI, 7.156-180.311; P<0.001), than in their benign counterparts.
  • [MeSH-major] Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787233.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Saifuku Y, Yamagata M, Koike T, Hitomi G, Kanke K, Watanabe H, Murohisa T, Tamano M, Iijima M, Kubota K, Hiraishi H: Endoscopic ultrasonography can diagnose distal biliary strictures without a mass on computed tomography. World J Gastroenterol; 2010 Jan 14;16(2):237-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasonography can diagnose distal biliary strictures without a mass on computed tomography.
  • AIM: To assess the diagnostic ability of endoscopic ultrasonography (EUS) for evaluating causes of distal biliary strictures shown on endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP), even without identifiable mass on computed tomography (CT).
  • METHODS: The diagnostic ability of EUS was retrospectively analyzed and compared with that of routine cytology (RC) and tumor markers in 34 patients with distal biliary strictures detected by ERCP or MRCP at Dokkyo Medical School Hospital from December 2005 to December 2008, without any adjacent mass or eccentric thickening of the bile duct on CT that could cause biliary strictures.
  • Findings considered as benign strictures on EUS included preservation of the normal sonographic layers of the bile duct wall, irrespective of the presence of a mass lesion.
  • RESULTS: Seventeen patients (50%) were finally diagnosed with benign conditions, including 6 "normal" subjects, while 17 patients (50%) were diagnosed with malignant disease.
  • In terms of diagnostic ability, EUS showed 94.1% sensitivity, 82.3% specificity, 84.2% positive predictive value, 93.3% negative predictive value (NPV) and 88.2% accuracy for identifying malignant and benign strictures.
  • In addition, EUS provided significantly higher sensitivity than tumor markers using 100 U/mL as the cutoff level of carbohydrate antigen 19-9 (94.1% vs 53%, P = 0.017).
  • On EUS, biliary stricture that was finally diagnosed as malignant showed as a hypoechoic, irregular mass, with obstruction of the biliary duct and invasion to surrounding tissues.
  • CONCLUSION: EUS can diagnose biliary strictures caused by malignant tumors that are undetectable on CT.
  • [MeSH-major] Biliary Tract Diseases / ultrasonography. Biliary Tract Neoplasms / ultrasonography. Endosonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract / ultrasonography. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Constriction, Pathologic / epidemiology. Constriction, Pathologic / ultrasonography. Female. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Oct;52(4):534-40 [11023576.001]
  • [Cites] Am J Gastroenterol. 2000 Mar;95(3):605-16 [10710047.001]
  • [Cites] Gut. 2002 Mar;50(3):326-31 [11839709.001]
  • [Cites] Gut. 2002 Aug;51(2):240-4 [12117887.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):372-9 [12196775.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):681-7 [12397276.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6 Suppl):S213-7 [12447270.001]
  • [Cites] Am J Gastroenterol. 2004 Jun;99(6):1069-73 [15180727.001]
  • [Cites] Gastrointest Endosc. 1988 Jan-Feb;34(1):19-22 [3280393.001]
  • [Cites] Gastrointest Endosc. 1998 May;47(5):341-9 [9609424.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Endoscopy. 2005 Aug;37(8):715-21 [16032489.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):71-7 [16377319.001]
  • [Cites] Gastrointest Endosc. 2006 Mar;63(3):403-8 [16500387.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):227-51 [16549326.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):968-73; discussion 974 [17043274.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):53-60 [17456835.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):90-6 [17451708.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):7-14 [18274839.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):31-40 [18274842.001]
  • [Cites] AJR Am J Roentgenol. 2008 Apr;190(4):1003-9 [18356448.001]
  • [Cites] Gut. 2007 Oct;56(10):1460-9 [17872573.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1577-82 [18000509.001]
  • [Cites] Scand J Gastroenterol. 2000 Jan;35(1):77-82 [10672839.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):475-84 [11275889.001]
  • (PMID = 20066744.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2806563
  •  go-up   go-down


28. Pertile D, Scabini S, Romairone E, Scordamaglia R, Rimini E, Ferrando V: Gastric Abrikosoff tumor (granular cell tumor): case report. G Chir; 2010 Oct;31(10):433-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Abrikosoff tumor (granular cell tumor): case report.
  • Granular Cells Tumor (GCT), also called Abrikosoff tumor, is very uncommon lesion of neural derivation.
  • It is characterized by the presence of granular cell; benign and malignamt counterparts are known, even if the second ones are rare.
  • Any localisation is possible, although surface lesions (head, neck, trunk, extremities) are far more common than visceral ones (esophagus, stomach, small and large bowel, larynx, bronchi, gallbladder and biliary tract).
  • Surgical en-block excision is curative for both benign an malignant forms.
  • We report the case of a 45 year old man who had a cytologic diagnosis of fusocellular stromal tumor of the gastric fundus during examination for gastritis.
  • [MeSH-major] Granular Cell Tumor. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939949.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M, Hamasaki N, Tanaka M: [Urine diacetylspermine as a novel tumor marker]. Rinsho Byori; 2005 Feb;53(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urine diacetylspermine as a novel tumor marker].
  • A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies.
  • Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia.
  • The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%.
  • These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / urine. Genital Neoplasms, Female / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pancreatic Neoplasms / diagnosis. Spermine / analogs & derivatives. Spermine / urine

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796046.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  • [Number-of-references] 6
  •  go-up   go-down


30. Nanashima A, Takeshita H, Tobinaga S, Araki M, Sumida Y, Kunizaki M, Tanaka K, Abo T, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies. Hepatogastroenterology; 2010 Jul-Aug;57(101):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the significance of 1CTP in hepato-biliary pancreas malignancies, we examined the relationship between clinicopathological features and serum level of 1CTP.
  • METHODOLOGY: The subjects were 75 patients who underwent surgical resections including 27 patients with liver carcinomas, 15 with extra-hepatic biliary carcinomas, 14 pancreatic carcinomas and 19 benign diseases.
  • RESULTS: 1CTP level tended to be higher in the malignant diseases than in benign diseases but this difference was not significant (p = 0.065).
  • Compared to benign adenoma, 1CTP level in the malignant diseases was significantly higher (p = 0.049).
  • 1CTP level tended to be higher in patients with cholangitis compared to those with no inflammation or benign tumors (p = 0.065).
  • 1CTP was not correlated with any tumor markers.
  • [MeSH-major] Biliary Tract Neoplasms / pathology. Biomarkers / blood. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / blood. Liver Neoplasms / pathology. Pancreatic Neoplasms / pathology. Peptides / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangitis / blood. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033212.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


31. Isomura Y, Yamaji Y, Ohta M, Seto M, Asaoka Y, Tanaka Y, Sasaki T, Nakai Y, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M, Koike K: A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol; 2010 Oct;45(10):1045-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
  • Based on this screening investigation suggesting an association with biliary tract cancer, we conducted a related study by recruiting 65 patients with biliary tract cancer and 566 patients with benign diseases as controls.
  • RESULTS: Among the 114 cell lines investigated, biliary tract cancer was suggested to be most strongly associated with poor metabolizers of CYP2C19.
  • Among 65 patients with biliary tract cancer, 18 (28%) were poor metabolizers of CYP2C19, whereas 87 (15%) of 566 control patients were poor metabolizers.
  • The age- and gender-adjusted odds ratios for intermediate and poor metabolizers regarding the risk of biliary tract cancer were 1.5 (95% CI: 0.8-3.0, P = 0.17) and 2.7 (1.3-5.9, P = 0.006) compared to extensive metabolizers.
  • CONCLUSIONS: A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Biliary Tract Neoplasms / genetics. Digestive System Neoplasms / genetics. Genetic Predisposition to Disease
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cell Line, Tumor. Cytochrome P-450 CYP2C19. Female. Humans. Male. Middle Aged. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1993 Jul;266(1):52-9 [8331574.001]
  • [Cites] Clin Pharmacol Ther. 1991 Jan;49(1):18-23 [1988236.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):407-11 [12402311.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):124-8 [12144816.001]
  • [Cites] Lancet. 2009 Jan 24;373(9660):309-17 [19108880.001]
  • [Cites] FEBS Lett. 1990 Apr 9;263(1):131-3 [1691986.001]
  • [Cites] Cancer Lett. 2001 Apr 26;165(2):171-7 [11275366.001]
  • [Cites] Clin Pharmacol Ther. 1999 May;65(5):552-61 [10340921.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1013-8 [9829710.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):495-500 [10385138.001]
  • [Cites] Clin Pharmacol Ther. 1989 Apr;45(4):348-55 [2495208.001]
  • [Cites] Pharmacogenetics. 1994 Apr;4(2):58-63 [7915935.001]
  • [Cites] Jpn J Clin Oncol. 2000 Dec;30(12):576 [11210170.001]
  • [Cites] Br J Clin Pharmacol. 1999 Sep;48(3):402-8 [10510153.001]
  • [Cites] Clin Pharmacol Ther. 1996 Jun;59(6):647-53 [8681489.001]
  • [Cites] Clin Investig. 1994 Feb;72(3):240-8 [7912124.001]
  • [Cites] N Engl J Med. 2009 Jan 22;360(4):354-62 [19106084.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4797 [1891387.001]
  • [Cites] Clin Pharmacol Ther. 1989 Jan;45(1):72-9 [2910639.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 15;22(10 ):1033-40 [16268979.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10 (13):1961-3 [15222046.001]
  • [Cites] Chem Res Toxicol. 2006 Jan;19(1):111-6 [16411663.001]
  • [Cites] Tohoku J Exp Med. 1990 May;161(1):69-71 [2396258.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):70-5 [18176964.001]
  • [Cites] Yakugaku Zasshi. 1995 Jan;115(1):1-14 [7699577.001]
  • [Cites] Br J Clin Pharmacol. 1995 Nov;40(5):481-5 [8703653.001]
  • [Cites] Pharmacogenetics. 2000 Oct;10 (7):605-15 [11037802.001]
  • [Cites] Int J Clin Pharmacol Ther. 2006 Jul;44(7):297-302 [16961157.001]
  • [Cites] Clin Pharmacol Ther. 1996 Dec;60(6):661-6 [8988068.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):852-7 [9307183.001]
  • [Cites] Life Sci. 2000 Feb 25;66(14 ):PL175-81 [10755474.001]
  • [Cites] Nihon Eiseigaku Zasshi. 1994 Feb;48(6):1090-8 [8126930.001]
  • [Cites] Ann Intern Med. 1998 Dec 15;129(12 ):1027-30 [9867757.001]
  • [Cites] Am J Gastroenterol. 2000 Jun;95(6):1402-10 [10894571.001]
  • [Cites] Mol Pharmacol. 1994 Oct;46(4):594-8 [7969038.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15419-22 [8195181.001]
  • [Cites] Ther Drug Monit. 1994 Apr;16(2):214-5 [8009572.001]
  • [Cites] Lung Cancer. 2008 Feb;59(2):155-63 [17900751.001]
  • (PMID = 20549256.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2C19 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2C19
  •  go-up   go-down


32. Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, Batra SK, Swallow DM, Pereira SP: MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer; 2008 May 20;98(10):1675-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.
  • Alterations in epithelial mucin expression are associated with carcinogenesis, but there are few data in biliary tract cancer (BTC).
  • In pancreatic malignancy, MUC4 is a diagnostic and prognostic tumour marker, whereas MUC5AC has been proposed as a sensitive serological marker for BTC.
  • We assessed MUC4 and MUC5AC expression in (i) prospectively collected bile and serum specimens from 72 patients with biliary obstruction (39 BTC) by real-time reverse transcriptase-PCR (qPCR) and western blot analysis, and (ii) 79 archived biliary tissues (69 BTC) by immunohistochemistry.
  • In bile, MUC4 protein was detected in 27% of BTC and 29% of primary sclerosing cholangitis (PSC) cases, but not in other benign and malignant biliary diseases (P<0.01 and P=0.06).
  • qPCR revealed a 1.9-fold increased MUC4 mRNA expression in BTC patients' bile compared with benign disease.
  • In archived tissues, MUC4 protein was detected in 37% of BTC but in none of the benign samples (P=0.03).
  • Biliary MUC4 and serum MUC5AC are highly specific tumour-associated mucins that may be useful in the diagnosis and formulation of therapeutic strategies in BTC.
  • [MeSH-major] Bile / metabolism. Biliary Tract Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Mucins / blood. Mucins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Mucin 5AC. Mucin-4. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1505-15 [17461441.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Dig Dis Sci. 2001 Oct;46(10):2166-72 [11680592.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1004-11 [11923240.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Bioessays. 2003 Jan;25(1):66-71 [12508284.001]
  • [Cites] Cancer Lett. 2003 May 30;195(1):93-9 [12767517.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1438-43 [14508831.001]
  • [Cites] Hybrid Hybridomics. 2003 Oct;22(5):293-9 [14678646.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Essays Biochem. 1985;20:40-76 [3896779.001]
  • [Cites] Biochem J. 1996 Aug 15;318 ( Pt 1):319-24 [8761488.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):166-77 [15672420.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Aliment Pharmacol Ther. 2006 May 1;23(9):1287-96 [16629933.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19310-9 [16690615.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):29411-20 [16891313.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Cancer Lett. 2007 Mar 18;247(2):301-8 [16793202.001]
  • [Cites] Eur J Biochem. 2000 Jul;267(14):4536-44 [10880978.001]
  • (PMID = 18475301.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801588; United Kingdom / Cancer Research UK / / C24036/A7839
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-4; 0 / Mucins
  • [Other-IDs] NLM/ PMC2391120
  •  go-up   go-down


33. Isayama H: Current topics in pancreato-biliary endotherapy: what can we do? J Hepatobiliary Pancreat Surg; 2009;16(5):589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current topics in pancreato-biliary endotherapy: what can we do?
  • INTRODUCTION: Endotherapy is progressing steadily, especially for various pancreato-biliary diseases.
  • MATERIALS AND METHODS: Biliary covered metallic stent (CMS) has developed, and the indication of CMS placement is changing because of its removability.
  • CMS is effective not only for unresectable biliary malignancies but also for resectable tumors, benign biliary strictures, and benign pancreatic strictures.
  • Drug-eluting CMS can be used as anti-tumor agents.
  • Interventional endoscopic ultrasonography (EUS) has shifted the treatment paradigm because it is possible to approach lesions through the digestive tract wall.
  • Double- and single-balloon enteroscopy will be performed more frequently to treat the pancreato-biliary disorders in the patients with altered anatomy.
  • These procedures are of very great interest because they alter the treatment algorithms for many pancreato-biliary diseases.
  • [MeSH-major] Biliary Tract Diseases / therapy. Biliary Tract Diseases / ultrasonography. Endoscopy, Digestive System / methods. Pancreatic Diseases / therapy. Pancreatic Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543686.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 27
  •  go-up   go-down


34. Sezer K, Cakal E, Ozkaya M, Yaman E, Akbay E: Normal CA 19-9 levels in Hashimoto's thyroiditis. Asian Pac J Cancer Prev; 2009 Apr-Jun;10(2):315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well known that moderately increased concentrations of CA 19-9 can be found in 15-36 % of patients with benign conditions such as pancreatic, liver, biliary diseases and benign hydronephrosis.
  • Patients with malignancy, benign pancreas, liver, lung and biliary diseases, inflammatory bowel diseases, urinary tract infection, hydronephrosis, endometriosis, diabetes mellitus and chronic renal failure were excluded.
  • Although the American Society of Clinical Oncology does not recommend tumor markers like CA 19-9 in screening for malignancies, they may be used for this purpose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537903.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


35. Jain M, Aggarwal S, Singh S: Intra-abdominal cavernous lymphangiomatosis in Siamese twins: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):570-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphangioma is a benign tumor like condition which is a developmental anomaly, involving any site but rarely involves retroperitoneum and abdomen (< 5%).
  • No such reports have been found in literature, although other congenital anomalies do coexist in Siamese twins and have been reported such as biliary tract and respiratory tract anomalies.

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Abdominal Lymphangiomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883139.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


36. Keter D, Melzer E: Endoscopic ultrasound in clinical practice. Acta Gastroenterol Latinoam; 2008 Jun;38(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasonography (EUS) is an accurate technique for the diagnosis and staging of benign and malignant lesions in the gastrointestinal tract and the mediastinum.
  • The most useful indications of EUS are differentiation of submucosal tumors, staging for neoplasia, examination of the pancreato-biliary system and therapeutics.
  • EUS is useful for local staging of esophageal, gastric, duodenal, and rectal cancer using the TNM (tumor, node, metastases) system, as well as for diagnosing and staging of pancreatic lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697409.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 32
  •  go-up   go-down


37. Biesterfeld S, Deacu L: DNA image cytometry in the differential diagnosis of benign and malignant lesions of the bile duct, the pancreatic duct and the papilla of Vater. Anticancer Res; 2009 May;29(5):1579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA image cytometry in the differential diagnosis of benign and malignant lesions of the bile duct, the pancreatic duct and the papilla of Vater.
  • The value of DNA image cytometry in the differential diagnosis of benign and malignant epithelial lesions was tested analyzing 174 specimens from the biliary tract, the pancreatic ducts and the papilla of Vater.
  • RESULTS: In comparison with the benign cases (n=120), the mean values of all DNA cytometric variables were markedly increased in the malignant (n=54) (p<0.001).
  • An aneuploid DNA stemline was present in 76% of the tumor cases.
  • The occurrence of 9cEEs were completely restricted to malignant specimens (specificity: 100%), but only present in 50% of the tumor cases.
  • As an additional finding in some benign cases, DNA polyploidy up to 8c could be demonstrated (11/120, 9.2%).
  • CONCLUSION: DNA image cytometry represents a relevant tool in the objective identification of malignant changes of specimens of the biliary tract, the pancreatic duct or the papilla of Vater, if suitable variables are used for DNA data interpretation.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443369.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


38. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol; 2006 Mar 1;24(7):1152-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.
  • PURPOSE: Biliary tract adenocarcinomas (BTAs), although anatomically related, arise through ill-defined and possibly different location-related pathogenetic pathways.
  • METHODS: Tissue microarrays were prepared from paraffin-embedded surgical specimens with triplicate cores of BTA and benign tissue.
  • Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar cholangiocarcinoma (Hilar; n = 54), gallbladder (GB; n = 32), and distal bile duct (Distal; n = 19).
  • p27 expression decreased progressively from proximal to distal in the biliary tree and correlated with location-related differences in outcome; cyclin D1 and Bcl2 overexpression also varied according to anatomic site.
  • CONCLUSION: BTAs differentially express cell cycle-regulatory proteins based on tumor location and morphology.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biomarkers, Tumor / analysis. Cell Cycle Proteins / analysis. Cholangiocarcinoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cyclin D1 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-mdm2 / analysis. Survival Analysis. Tumor Suppressor Protein p53 / analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


39. Chen B, Dong JQ, Chen YJ, Wang JM, Tian J, Wang CB, Zou SQ: Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):402-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Proteomic analysis of bile fluid holds promise as a method to identify biomarkers of bile tract diseases, especially for tumors.
  • Two-dimensional electrophoresis (2-DE) is a popular and proven separation technique for proteome analysis, but using this strategy for bile fluid analysis is still not fully developed.
  • This study was undertaken to (a) establish a reliable method for general clean-up to make bile fluid samples suitable for 2-DE;.
  • (b) obtain 2-D biliary maps with high reproducibility and resolution; and (c) identify protein patterns present in 2-D biliary maps for potential tumor biomarker discovery, with the intention of distinguishing malignant from benign causes of bile duct obstruction.
  • METHODS: Bile fluid samples were obtained from two patients suffering from malignant and benign bile tract obstruction (one patient with cholangiocarcinoma as the experimental case, the other with cholelithiasis as control).
  • A variety of sample preparation options, including delipidation, desalination and nucleic acid removal, were adopted to remove contaminants that affect 2-DE results.
  • CONCLUSIONS: This study established a reliable sample preparation process suitable for 2-DE of bile fluid.
  • By this method, 2-D biliary maps with high reproducibility and resolution were obtained.
  • The differentially displayed proteomes in the 2-D biliary maps from the experimental and control groups indicated the potential application for bile fluid analysis to identify disease-associated biomarkers, especially for biliary tract tumors.
  • [MeSH-minor] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / metabolism. Humans. Hydrogen-Ion Concentration. Isoelectric Focusing / methods. Peptide Mapping. Proteome. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690038.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


40. Ozkan H, Akar T, Köklü S, Coban S: Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology; 2006;6(4):268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases.
  • BACKGROUND/AIMS: RCAS1 is a novel tumor marker, and there are no sufficient data about the utility of this antigen as a serum tumor marker and about its tumor specificity.
  • METHODS: Sera collected from patients with pancreas adenocarcinomas (39 cases) and benign biliary and pancreatic diseases (19 cases) and from healthy volunteers (13 cases) were analyzed for RCAS1 and the results compared with CA19-9.
  • The relation between serum RCAS1 and tumor stage was also evaluated.
  • RESULTS: The serum RCAS1 levels exceeded the normal limit in 92.3, 26.3, and 23.0% of the patients with pancreatic cancer and benign biliary and pancreatic diseases and healthy volunteers, respectively.
  • Both tumor markers had similar predictive values of positive and negative tests for pancreatic cancer.
  • The RCAS1 level was less influenced than the CA19-9 level by biliary stenoses.
  • The median serum levels of RCAS1 increased, as the tumor stage increased.
  • [MeSH-major] Antigens, Neoplasm / blood. Biliary Tract Diseases / diagnosis. Biomarkers, Tumor / blood. Pancreatic Diseases / diagnosis. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16636598.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / EBAG9 protein, human
  •  go-up   go-down


41. Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, Chantawibul S, Tepaksorn P: Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol; 2006 Jul 14;12(26):4195-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients.
  • METHODS: The serum of thirty three cholangiocarcinoma patients, forty one benign biliary tract disease patients and ten healthy volunteers were collected and analyzed for the expression of hTERT mRNA by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RESULTS: hTERT mRNA was detected in 28 of 33 (84.85%) of serum obtained from cholangiocarcinoma patients and 9 of 41 (21.9%) of serum obtained from benign biliary tract disease patients. hTERT mRNA was not detected in any serum obtained from healthy volunteers. on the other hand the common tumor marker, CA19-9 was detected in 20 of 33 (60.6%) of serum obtained from cholangiocarcinoma patients and 8 of 41 (19.5%) of serum obtained from benign biliary tract disease patients.
  • However, no correlation was found between the present of serum hTERT mRNA and tumor staging.
  • It offers a novel tumor marker, which can be used as a complementary study for diagnosis of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / blood. Biomarkers, Tumor / blood. Cholangiocarcinoma / blood. DNA-Binding Proteins / genetics. RNA, Messenger / blood. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts, Intrahepatic. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):55-66 [10674450.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3823-6 [11051224.001]
  • [Cites] Nucleic Acids Res. 2001 Aug 15;29(16):3385-93 [11504876.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:179-88 [11708476.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1186-93 [12142371.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Nov;5(6):907-16 [16255632.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3166-70 [10397260.001]
  • [Cites] Acta Otolaryngol. 2005 Apr;125(4):409-14 [15823813.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):611-22 [16136653.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):276-81 [16235986.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):245-52 [14654933.001]
  • (PMID = 16830373.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC4087372
  •  go-up   go-down


42. Ayaru L, Stoeber K, Webster GJ, Hatfield AR, Wollenschlaeger A, Okoturo O, Rashid M, Williams G, Pereira SP: Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer; 2008 May 06;98(9):1548-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary brush cytology is the standard method of sampling a biliary stricture but has a low sensitivity for the detection of malignancy.
  • In 30 tissue specimens from patients with malignant/benign biliary strictures, we studied Mcm2 and -5 expression by immunohistochemistry.
  • Bile samples were also collected prospectively at endoscopic retrograde cholangiopancreatography from 102 consecutive patients with biliary strictures of established (n=42) or indeterminate aetiology (n=60).
  • In benign biliary strictures, Mcm2 and -5 protein expression was confined to the basal epithelial proliferative compartment - in contrast to malignant strictures where expression was seen in all tissue layers.
  • The percentage of nuclei positive for Mcm2 was higher in malignant tissue (median 76.5%, range 42-92%) than in benign tissue (median 5%, range 0-33%) (P<0.0005), with similar results for Mcm5.
  • [MeSH-major] Bile / chemistry. Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Cell Cycle Proteins / analysis. Nuclear Proteins / analysis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):552-61 [12297773.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:20-4 [10466756.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] Gut. 2004 Dec;53(12):1727-9 [15542504.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):78-80 [16377320.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2006 Feb;3(2):74-5 [16456571.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):720-30 [12397282.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):45-51 [14687140.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1464-9 [15307861.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):565-72 [8674929.001]
  • [Cites] Gut. 1997 May;40(5):671-7 [9203949.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 16;1398(2):113-36 [9689912.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):383-90 [10744806.001]
  • (PMID = 18414413.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801588; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2391096
  •  go-up   go-down


43. Yamaguchi K, Nakamura M, Shirahane K, Konomi H, Torata N, Hamasaki N, Kawakita M, Tanaka M: Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas. Dig Liver Dis; 2005 Mar;37(3):190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
  • BACKGROUND: Serum carcinoembryonic antigen (highly specific) and carbohydrate antigen 19-9 (highly sensitive) have been used as tumour markers for pancreatobiliary cancers.
  • A novel urine tumour marker, diacetylspermine, was compared with the two conventional serum tumour markers in 125 patients with pancreatobiliary diseases.
  • RESULTS: When the diagnosis of benign or malignant condition was examined, the sensitivity of urine diacetylspermine (75%) was higher than that of serum carcinoembryonic antigen (44%; P=0.048) and the same as that of serum carbohydrate antigen 19-9 (75%).
  • [MeSH-major] Biliary Tract Neoplasms / urine. Biomarkers, Tumor / urine. Pancreatic Neoplasms / diagnosis. Spermine / analogs & derivatives. Spermine / urine

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888284.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


44. Ulla Rocha JL, Alvarez Sanchez MV, Paz Esquete J, Fernandez Salgado E, Alvarez Alvarez C, Vazquez Sanluis MJ, Ledo Barro L, Vazquez Astray E: Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation. JOP; 2007;8(2):191-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: When EUS was indicated for the asymptomatic elevation of CA 19-9, the main findings were benign diseases.
  • [MeSH-major] Abdominal Pain / ultrasonography. Biliary Tract Diseases / ultrasonography. CA-19-9 Antigen / blood. Endosonography. Pancreatitis, Chronic / ultrasonography
  • [MeSH-minor] Acute Disease. Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Biomarkers, Tumor / blood. Biopsy, Fine-Needle. Humans. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356242.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


45. Nakao A, Takeda S, Nomoto S, Kanazumi N, Kasuya H, Sugimoto H, Fujii T, Yamada S: Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):788-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: We have experienced 67 cases of pancreatic head resection with segmental duodenectomy (PHRSD) for benign or low-grade malignant tumor of the pancreatic head region.
  • Reconstruction of the alimentary tract is performed with pancreatogastrostomy, end-to-end duodenoduodenostomy and end-to-side choledochoduodenostomy.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / surgery. Choledochostomy / methods. Follow-Up Studies. Humans. Neoplasm Staging. Quality of Life. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882374.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Robertson AG, Davidson BR: Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9. Eur J Gastroenterol Hepatol; 2007 Feb;19(2):167-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9.
  • After biliary stenting, the CA19-9 returned to normal.
  • At surgery, biliary obstruction owing to a gallstone (Type II Mirizzi) was found to be complicating a congenital biliary tract anomaly.
  • The obstructing stone was removed and the anomalous biliary tract reconstructed with a Roux-en-y loop, and the patient made an uneventful recovery and remained normal over a 2-year follow-up.
  • A Type II Mirizzi with a biliary tract anomaly is an undocumented cause of an elevated CA19-9.
  • The possibility of benign disease must be considered even with very high levels of the cancer marker CA19-9 or the opportunity for curative surgery may be missed.
  • [MeSH-major] Biliary Tract / abnormalities. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Gallbladder Neoplasms / diagnosis. Gallstones / diagnosis

  • Genetic Alliance. consumer health - Mirizzi syndrome.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273004.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


47. Siablis D, Papathanassiou ZG, Karnabatidis D, Christeas N, Vagianos C: Hemobilia secondary to hepatic artery pseudoaneurysm: an unusual complication of bile leakage in a patient with a history of a resected IIIb Klatskin tumor. World J Gastroenterol; 2005 Sep 7;11(33):5229-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemobilia secondary to hepatic artery pseudoaneurysm: an unusual complication of bile leakage in a patient with a history of a resected IIIb Klatskin tumor.
  • We report a case of a 74-year-old woman with a 16-year history of a double bilo-enteric anastomosis due to resected hilar cholangiocarcinoma (Type IIIb Klatskin tumor).
  • The patient presented with cholangitis secondary to benign anastomotic stenosis which resulted in a large intrahepatic biloma.
  • This had ruptured into the biliary tract, and presented the actual cause of the hemobilia.
  • [MeSH-major] Aneurysm, False / complications. Bile / metabolism. Bile Duct Neoplasms / surgery. Hemobilia / etiology. Hepatic Artery. Hepatic Duct, Common. Klatskin Tumor / surgery. Postoperative Complications

  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127759.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4320402
  •  go-up   go-down


48. Chun HJ, Kim ES, Hyun JJ, Kwon YD, Keum B, Kim CD: Gastrointestinal and biliary stents. J Gastroenterol Hepatol; 2010 Feb;25(2):234-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal and biliary stents.
  • Advances in stent design have led to a substantial increase in the use of stents for a variety of malignant and benign strictures in the gastrointestinal tract and biliary system.
  • Covered stents have been introduced to minimize tumor ingrowth through the metal mesh but are associated with higher rates for spontaneous migration.
  • [MeSH-major] Biliary Tract Diseases / surgery. Biliary Tract Surgical Procedures / instrumentation. Digestive System Surgical Procedures / instrumentation. Gastrointestinal Diseases / surgery. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20136988.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 83
  •  go-up   go-down


49. Lefkowitch JH: Advances in hepatobiliary pathology: update for 2010. Clin Liver Dis; 2010 Nov;14(4):747-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advances in diagnosis and pathogenesis of primary biliary cirrhosis, primary sclerosing cholangitis, and the increasingly complex spectrum of IgG4 hepatobiliary diseases were also reported.
  • The histologic and immunohistochemical features of the rare "calcifying nested stromal-epithelial tumor" of the liver were described in a 9-case series.
  • For benign and malignant liver tumors, immunohistochemistry plays a major diagnostic role, and several recent studies demonstrate the value of immunostains in distinguishing between liver-cell adenoma and focal nodular hyperplasia.
  • [MeSH-major] Biliary Tract / pathology. Biopsy / methods. Immunohistochemistry / methods. Liver / pathology. Liver Diseases / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 21055694.001).
  • [ISSN] 1557-8224
  • [Journal-full-title] Clinics in liver disease
  • [ISO-abbreviation] Clin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


50. Cheng CL, Fogel EL, Sherman S, McHenry L, Watkins JL, Croffie JM, Gupta SK, Fitzgerald JF, Lazzell-Pannell L, Schmidt S, Lehman GA: Diagnostic and therapeutic endoscopic retrograde cholangiopancreatography in children: a large series report. J Pediatr Gastroenterol Nutr; 2005 Oct;41(4):445-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications included biliary pathology (n = 93), pancreatic pathology (n = 111), and chronic abdominal pain of suspected biliary or pancreatic origin (n = 41).
  • The ERCP findings were bile duct stone(s) (n = 29), benign biliary stricture (n = 19), primary sclerosing cholangitis (n = 7), anomalous pancreaticobiliary union (n = 8), choledochal cyst (n = 5), bile duct leak (n = 6), malignant biliary stricture (n = 2), biliary atresia (n = 1), chronic pancreatitis (n = 44), pancreas divisum (n = 26), pancreatic duct stricture with (n = 6) or without (n = 9) leak, pancreatic tumor (n = 1), periampullary adenoma (n = 2), and sphincter of Oddi dysfunction (n = 65).
  • [MeSH-major] Biliary Tract Diseases / diagnosis. Biliary Tract Diseases / therapy. Cholangiopancreatography, Endoscopic Retrograde. Pancreatic Diseases / diagnosis. Pancreatic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205513.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Leelawat K, Sakchinabut S, Narong S, Wannaprasert J: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol; 2009;9:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cholangiocarcinoma is an aggressive tumor with a tendency for local invasion and distant metastases.
  • However, at present, there is no available tumor marker that can differentiate cholangiocarcinoma from benign bile duct disease.
  • METHODS: This study was designed to determine whether the serum levels of MMP-7 and MMP-9 can discriminate cholangiocarcinoma patients from benign biliary tract disease patients in comparison to carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).
  • We measured the level of CEA, CA19-9, MMP-7 and MMP-9 in the serum of 44 cholangiocarcinoma and 36 benign biliary tract diseases patients.
  • RESULTS: Among the serum levels of CEA, CA19-9, MMP-7 and MMP-9, only the serum MMP-7 level was significantly higher in the patients with cholangiocarcinoma (8.9 +/- 3.43 ng/ml) compared to benign biliary tract disease patients (5.9 +/- 3.03 ng/ml) (p < 0.001).
  • An receiver operating characteristic (ROC) curve analysis revealed that the detection of the serum MMP-7 level is reasonably accurate in differentiating cholangiocarcinoma from benign biliary tract disease patients (area under curve = 0.73; 95% CI = 0.614-0.848).
  • CONCLUSION: Serum MMP-7 appears to be a valuable diagnostic marker in the discrimination of cholangiocarcinoma from benign biliary tract disease.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Biliary Tract Diseases / diagnosis. Biomarkers, Tumor / blood. Cholangiocarcinoma / diagnosis. Matrix Metalloproteinase 7 / blood. Matrix Metalloproteinase 9 / blood

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2008 Mar;54(3):574-81 [18202161.001]
  • [Cites] Clin Liver Dis. 2008 Feb;12(1):131-50, ix [18242501.001]
  • [Cites] Curr Opin Gastroenterol. 2008 May;24(3):349-56 [18408464.001]
  • [Cites] Hum Pathol. 2008 May;39(5):710-9 [18329694.001]
  • [Cites] Can J Gastroenterol. 2008 Aug;22(8):689-98 [18701947.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] Dig Dis Sci. 2008 Dec;53(12):3213-7 [18465243.001]
  • [Cites] World J Surg. 2008 Dec;32(12):2675-80 [18843437.001]
  • [Cites] J Hepatol. 2009 Jan;50(1):158-64 [19012991.001]
  • [Cites] Dig Dis Sci. 2009 Jun;54(6):1203-7 [18719998.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] Mol Med Today. 2000 Apr;6(4):149-56 [10740253.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1259-62 [14571713.001]
  • [Cites] Anal Biochem. 2003 Nov 15;322(2):283-6 [14596841.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):68-75 [14687144.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):411-24 [15349816.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:212-27 [10415733.001]
  • [Cites] Korean J Gastroenterol. 2005 Jan;45(1):52-9 [15665568.001]
  • [Cites] Transplantation. 2005 Mar 27;79(6):745-6 [15785393.001]
  • [Cites] Tumori. 2006 Mar-Apr;92(2):149-54 [16724695.001]
  • [Cites] Dig Surg. 2006;23(5-6):319-24 [17170527.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1066-71 [17487834.001]
  • [Cites] PLoS Med. 2007 Jul;4(7):e201 [17622191.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1591-5 [17708308.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1174-84 [17919228.001]
  • [Cites] Clin Chim Acta. 2008 Mar;389(1-2):61-6 [18155162.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2050-6 [18172859.001]
  • (PMID = 19405942.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2680894
  •  go-up   go-down


52. Kelemen D, Horváth OP: Experiences with single-layer biliodigestive anastomosis. Hepatogastroenterology; 2005 May-Jun;52(63):683-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 96 cases the diagnosis was tumor, while the others were benign diseases.
  • There were complications in 29.4% of the cases, from which the rate of biliary fistula was 3.9%.
  • [MeSH-major] Anastomosis, Surgical / methods. Biliary Tract Neoplasms / surgery. Cholestasis / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966182.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


53. van Gulik TM, Kloek JJ, Ruys AT, Busch OR, van Tienhoven G, Lameris JS, Rauws EA, Gouma DJ: [Improved treatment results in hilar cholangiocarcinoma after transition to more extensive procedure: 20 years experience AMC]. Ned Tijdschr Geneeskd; 2010;154:A1815
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the result of surgical treatment of patients with hilar cholangiocarcinoma (HCCA) before and after the transition from predominantly local bile duct resections to more extensive resections including partial liver resection in order to achieve complete tumour resection in the Academic Medical Center, Amsterdam (The Netherlands).
  • Preoperative work-up included staging laparoscopy, preoperative biliary drainage and short-course radiation therapy (3 x 3.5 Gy) to prevent seeding metastases.
  • RESULTS: In 18 patients (15.3%) a benign lesion was found in the resection specimen.
  • The margin tumour free resection rate increased from 20% in period 1 to 59% in period 2.
  • [MeSH-minor] Adult. Aged. Biliary Tract Surgical Procedures. Female. Follow-Up Studies. Humans. Klatskin Tumor / mortality. Klatskin Tumor / surgery. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858305.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Beger HG, Rau BM, Gansauge F, Poch B: Duodenum-preserving subtotal and total pancreatic head resections for inflammatory and cystic neoplastic lesions of the pancreas. J Gastrointest Surg; 2008 Jun;12(6):1127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: For treatment of inflammatory and benign neoplastic lesions of the pancreatic head, a subtotal or total pancreatic head resection is a limited surgical procedure with the impact of replacing the application of a Whipple procedure.
  • The advantages of this limited surgical procedure are the preservation of the stomach, the duodenum and the extrahepatic biliary ducts for treatment of benign lesions of the pancreatic head, papilla, and intrapancreatic segment of the common bile duct.
  • Performing, in addition, a biliary anastomosis or a Partington Rochelle type of pancreatic main duct drainage, respectively, is a logic and simple extension of the procedure.
  • The rationale for the application of duodenum-preserving total pancreatic head resection for cystic neoplastic lesions are complete exstirpation of the tumor and, as a consequence, interruption of carcinogenesis of the neoplasia preventing development of pancreatic cancer.
  • Duodenum-preserving total head resection necessitates additional biliary and duodenal anastomoses.
  • CONCLUSION: The limited surgical procedures of subtotal or total pancreatic head resection are simple, safe, ensures free tumour margins and replace in the authors institution the application of a Whipple-type head resection.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1989 Mar;209(3):273-8 [2923514.001]
  • [Cites] Chirurg. 1980 May;51(5):303-7 [7408575.001]
  • [Cites] Pancreas. 1987;2(6):701-7 [3438308.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):533-5 [9638444.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):156-62 [14505149.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):512-9; discussion 519-23 [10522721.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):350-8 [7726670.001]
  • [Cites] Chirurg. 1987 Jan;58(1):7-13 [3549190.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):710-5 [15862268.001]
  • [Cites] Surgery. 2003 Jul;134(1):53-62 [12874583.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):213-9 [9488519.001]
  • [Cites] Chirurgie. 1981;107(8):597-604 [7327022.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):771-9 [9860476.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):356-9 [8406305.001]
  • [Cites] Dig Surg. 2001;18(1):21-5 [11244255.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):149-56 [18392707.001]
  • [Cites] Chirurg. 1995 Apr;66(4):350-9 [7634946.001]
  • (PMID = 18299945.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


55. Riddle ND, Quigley BC, Browarsky I, Bui MM: Leiomyosarcoma arising in the pancreatic duct: a case report and review of the current literature. Case Rep Med; 2010;2010:252364
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Context. Leiomyosarcomas are rare malignant smooth muscle tumors that may arise in any organ or tissue that contains smooth muscle, commonly within the gastrointestinal tract.
  • The tumor clearly originated from the pancreatic duct wall, filled and expanded the duct lumen, and was covered with a layer of benign biliary epithelium.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tunis Med. 2005 May;83(5):288-91 [16044903.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1720-3 [7370927.001]
  • [Cites] Curr Surg. 2004 Nov-Dec;61(6):572-5 [15590026.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):548-51 [15661250.001]
  • [Cites] Urol Oncol. 2005 Jan-Feb;23(1):22-6 [15885579.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1226-9 [16343220.001]
  • [Cites] Urology. 2006 Feb;67(2):424.e13-424.e15 [16461113.001]
  • [Cites] J Foot Ankle Surg. 2006 Mar-Apr;45(2):127-30 [16513508.001]
  • [Cites] No Shinkei Geka. 2006 Apr;34(4):409-13 [16613223.001]
  • [Cites] Int Surg. 2005 Nov-Dec;90(5):262-5 [16625943.001]
  • [Cites] Cancer Radiother. 2006 May;10(3):137-41 [16330234.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):466-70 [16872443.001]
  • [Cites] Actas Urol Esp. 2006 Jun;30(6):638-40 [16921844.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Oct;263(10):929-34 [16804717.001]
  • [Cites] Arch Esp Urol. 2006 Sep;59(7):728-31 [17078398.001]
  • [Cites] Arch Esp Urol. 2006 Nov;59(9):908-10 [17190216.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):628-33 [17451590.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):634-7 [17451591.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):963-77 [17574946.001]
  • [Cites] Obstet Gynecol Surv. 2007 Jul;62(7):480-6 [17572920.001]
  • [Cites] World J Gastroenterol. 2008 May 14;14(18):2942-5 [18473429.001]
  • [Cites] Pancreas. 2008 Aug;37(2):230-1 [18665093.001]
  • [Cites] Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):158-61 [18720751.001]
  • [Cites] Korean J Radiol. 2007 Nov-Dec;8(6):541-4 [18071285.001]
  • [Cites] HPB (Oxford). 2002;4(3):145-8 [18332943.001]
  • [Cites] Radiat Med. 1999 May-Jun;17(3):239-41 [10440114.001]
  • [Cites] Abdom Imaging. 1999 May-Jun;24(3):299-300 [10227898.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2352-8 [10357405.001]
  • [Cites] Clin Lab Haematol. 1999 Jun;21(3):219-24 [10448606.001]
  • [Cites] Int J Pancreatol. 1999 Dec;26(3):193-9 [10732297.001]
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):189-92 [15221604.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Apr;96(4):286-7 [15259151.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):433-4 [15332041.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Sep;34(6):690-2 [16053897.001]
  • (PMID = 20589089.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892659
  •  go-up   go-down


56. Uhlmann D, Wiedmann M, Schmidt F, Kluge R, Tannapfel A, Berr F, Hauss J, Witzigmann H: Management and outcome in patients with Klatskin-mimicking lesions of the biliary tree. J Gastrointest Surg; 2006 Sep-Oct;10(8):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and outcome in patients with Klatskin-mimicking lesions of the biliary tree.
  • The preoperative and even intraoperative differentiation between benign and malignant strictures at the hepatic hilum remains difficult.
  • The aim of this study was to assess clinical, radiologic, intraoperative, and histopathologic findings; surgical treatment; and outcome of patients with Klatskin mimicking benign lesions.
  • Of 49 consecutive patients who were operated on the initial preoperative radiologic diagnosis of hilar adenocarcinoma (Klatskin tumor), 7 (14%) had benign conditions after final histopathologic diagnosis.
  • Clinical presentation and imaging assessment were similar for Klatskin tumors and benign fibrosing disease; therefore, an aggressive resectional approach is justified in any patient with suspicious obstruction of the liver hilum.
  • [MeSH-major] Bile Duct Neoplasms. Cholecystectomy / methods. Hepatectomy / methods. Hepatic Duct, Common. Klatskin Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):747-52 [2210678.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):230-9 [16858185.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54 [12173019.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1119-25 [11706073.001]
  • [Cites] Cancer. 1984 Apr 1;53(7):1545-51 [6365304.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):628-38 [8916878.001]
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):55-66 [10674450.001]
  • [Cites] Surg Gynecol Obstet. 1975 Feb;140(2):170-8 [1079096.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Gastrointest Endosc. 2002 Jul;56(1):48-54 [12085034.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Apr 15;21(8):933-48 [15813829.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):659-61 [4027545.001]
  • [Cites] Hepatology. 2001 May;33(5):1029-35 [11343227.001]
  • [Cites] Surgery. 1992 Nov;112(5):866-71 [1332203.001]
  • [Cites] Am J Gastroenterol. 1991 Feb;86(2):224-6 [1992639.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):849-52 [2765843.001]
  • [Cites] Radiology. 1995 Jun;195(3):705-9 [7753998.001]
  • [Cites] Nucl Med Commun. 2001 Dec;22(12 ):1277-85 [11711897.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jan;172(1):73-7 [9888743.001]
  • [Cites] Am J Surg. 1983 Sep;146(3):404-8 [6614339.001]
  • [Cites] Gut. 2000 Nov;47(5):721-7 [11034592.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):84-92 [12832969.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):48-51 [11136309.001]
  • [Cites] J Surg Res. 1999 Jun 1;84(1):88-93 [10334895.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):658-61 [14511613.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4264-7 [7671233.001]
  • [Cites] Hepatogastroenterology. 1987 Feb;34(1):5-9 [3570143.001]
  • [Cites] Pancreas. 2000 Mar;20(2):109-16 [10707924.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):808-18; discussion 819 [10615936.001]
  • [Cites] Am J Gastroenterol. 1981 May;75(5):370-2 [7270533.001]
  • [Cites] Eur J Surg Oncol. 1995 Oct;21(5):517-22 [7589597.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1075-84 [9508193.001]
  • [Cites] Radiology. 2004 Oct;233(1):234-40 [15333766.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jan;156(1):77-8 [1898573.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1158-63 [16000285.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • (PMID = 16966034.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Wen H, Yoo SS, Kang J, Kim HG, Park JS, Jeong S, Lee JI, Kwon HN, Kang S, Lee DH, Park S: A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol; 2010 Feb;52(2):228-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer.
  • BACKGROUND & AIMS: Biliary tract cancer is highly lethal at presentation, with increasing mortality worldwide.
  • Current diagnostic measures employing multiple criteria such as imaging, cytology, and serum tumor markers are not satisfactory, and a new diagnostic tool is needed.
  • Because bile is a cognate metabolite-rich bio-fluid in the biliary ductal system, we tested a new metabolomic approach to develop an effective diagnostic tool.
  • METHODS: Biles were collected prospectively from patients with cancer (n=17) or benign biliary tract diseases (n=21) with percutaneous or endoscopic methods.
  • RESULTS: The metabolomic 2-D score plot showed good separation between cancer and benign groups.
  • CONCLUSION: The NMR-based metabolomics approach provides good performance in discriminating cancer and benign biliary duct diseases.
  • [MeSH-major] Bile / metabolism. Biliary Tract Neoplasms / diagnosis. Biliary Tract Neoplasms / metabolism. Magnetic Resonance Spectroscopy / methods. Metabolomics / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biliary Tract Diseases / diagnosis. Biliary Tract Diseases / metabolism. Female. Humans. Least-Squares Analysis. Male. Middle Aged. Multivariate Analysis. Prospective Studies

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2011 Feb;54(2):398-9; author reply 399-400 [21112110.001]
  • (PMID = 20036026.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


58. Merenda R, Portale G, Galeazzi F, Tosolini C, Sturniolo GC, Ancona E: Pancreaticoduodenectomy for dysplastic duodenal adenoma in a patient with familial adenomatous polyposis. Tumori; 2008 Nov-Dec;94(6):882-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal polyposis is the main feature of familial adenomatous polyposis (FAP), but benign and malignant lesions have also been described in the stomach, duodenum, small bowel, biliary tract and pancreas.
  • This report described the rare case of a patient presenting with duodenal adenomas with dysplastic changes and tumor infiltration as the first sign of FAP, who was treated by pancreaticoduodenectomy followed by proctocolectomy for subsequent dysplastic changes in colonic polyps.






Advertisement